Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siPSMA-14
- Development stage
- Unknown
- Lead developer
- University Hospital Ulm
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
siPSMA-14 is a silicon-based, peptide-like radiopharmaceutical precursor designed to target prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II. Developed by researchers at the Technical University of Munich and Ulm University Hospital, and distributed by Scintomics, siPSMA-14 incorporates a silicon-fluoride acceptor (SiFA) moiety that allows for rapid, simple, and scalable radiolabeling with fluorine-18 ([18F]) via isotopic exchange. The resulting radiotracer, [18F]siPSMA-14, is used in positron emission tomography (PET) imaging for the primary staging and restaging of prostate cancer, including the detection of biochemical recurrence. It exhibits high tumor accumulation, favorable biodistribution, and low urinary background activity, enabling high-contrast imaging without the need for forced diuresis.
- Other names
- 18F-siPSMA-14F-18 siPSMA-14F18 siPSMA-14F 18 siPSMA-14[18F]F-siPSMA-14[18F]siPSMA-14fluorine-18 siPSMA-14fluorine18 siPSMA-14fluorine 18 siPSMA-14
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on siPSMA-14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siPSMA-14.